bioRxivImmunologyPreprint
Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti-CD19-AntiCD3 Diabody
Tonny Johnson, Armin AhnoudiD, Beth DiNello, P Ralph, Timothy P. CripeiD, Pin-Yi WangiD, Tania L. WeissiD
Abstract
GP101 is a single chain diabody composed of Fv regions of antibodies directed to CD3 and CD19. It is designed to mimic commercial blinatumomab (Blincyto(R)) that simultaneously co-engages patient T lymphocytes and CD19 positive B cell leukemias and lymphomas, facilitating their targeted destruction. This study details the purification of GP101 protein and development of a highly sensitive ELISA for its detection, achieving a sensitivity of 15pg/mL in 25% mouse serum. This ELISA has been validated according to GLP standards.
- organism: mouse
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody
Tania L. Weiss, Justine Paniagua, … P Ralph·Journal of Immunological MethodsPeer-reviewed·Nov 14, 2025
- Preclinical Basis of the Efficacy and Pharmacodynamics of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody with Potent Implications for Clinical Benefit
- Inhibition of dipeptidyl peptidase 4 allows accurate measurement of GLP-1 secretion in mice
M. M. Smits, K. D. Galsgaard, … J. J. Holst·bioRxiv·Oct 19, 2023
- A new long-acting GLP-1 derivative 6- KTP ameliorates body weight and lipid metabolism in DIO mice
- Generation of High-Affinity Anti-GIPR Antagonist Antibodies with Sustained and Non-rebound Weight Loss in DIO Mice by AlfaBodY
Yongkang Long, Zhangzhan Xu, … Liang Chen·bioRxiv·Apr 24, 2026
- Rational design by structural biology of industrializable, long-acting antihyperglycemic GLP-1 receptor agonists
L. Sun, Z.-M. Zheng, … P. Wang·bioRxiv·Apr 11, 2022